Adeno-associated Virus Vectors in Gene Therapy Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Adeno-associated Virus Vectors in Gene Therapy pipeline constitutes key companies continuously working towards developing Adeno-associated Virus Vectors in Gene Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Adeno-associated Virus Vectors in Gene Therapy Overview
Adeno-associated virus (AAV) was first discovered from laboratory adenovirus (AdV) preparations in the mid-1960s and Therapy- Overview found in human tissues soon after3. Driven by pure scientific curiosity and without realizing its tremendous potential as a human gene therapy platform, a few research groups embarked on a journey to understand basic AAV biology.

"Adeno-associated Virus Vectors in Gene Therapy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adeno-associated Virus Vectors in Gene Therapy Market.

The Adeno-associated Virus Vectors in Gene Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Adeno-associated Virus Vectors in Gene Therapy Pipeline Report: https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Adeno-associated Virus Vectors in Gene Therapy treatment therapies with a considerable amount of success over the years. Adeno-associated Virus Vectors in Gene Therapy Key players such as - Asklepios Biopharmaceutical, MeiraGTx, Gyroscope Therapeutics, Nanoscope Therapeutics, Neurophth biological tech, Lysogene, Spark Therapeutics, and others, are developing therapies for the Adeno-associated Virus Vectors in Gene Therapy treatment
• Adeno-associated Virus Vectors in Gene Therapy Emerging therapies such as - AAV2/8LSPhGAA, AAV CNGA3, GT 005, MCO-010, NFS-01, LYS-SAF302, SPK-9001, SPK-8011, and others are expected to have a significant impact on the Adeno-associated Virus Vectors in Gene Therapy market in the coming years.
• In January 2021, MeiraGTx announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene.
• In April, 2021 Neurophth announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the Company's Investigational New Drug (IND) application of NR082 for LHON patients with ND4 mutations
• In June 2021, Wuhan Neurophth Biotechnology Limited Company initiated a Phase I/II/III, single arm, multi-center, two-stage clinical trial to evaluate the safety and efficacy of Gene Therapy for Leber Hereditary Optic Neuropathy (LHON) associated with ND4 mutation

Route of Administration
Adeno-associated Virus Vectors in Gene Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Adeno-associated Virus Vectors in Gene Therapy Pipeline Therapeutics Assessment
• Adeno-associated Virus Vectors in Gene Therapy Assessment by Product Type
• Adeno-associated Virus Vectors in Gene Therapy By Stage and Product Type
• Adeno-associated Virus Vectors in Gene Therapy Assessment by Route of Administration
• Adeno-associated Virus Vectors in Gene Therapy By Stage and Route of Administration
• Adeno-associated Virus Vectors in Gene Therapy Assessment by Molecule Type
• Adeno-associated Virus Vectors in Gene Therapy by Stage and Molecule Type

DelveInsight's Adeno-associated Virus Vectors in Gene Therapy Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Adeno-associated Virus Vectors in Gene Therapy Therapeutics Market include:
Key companies developing therapies for Adeno-associated Virus Vectors in Gene Therapy are - Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S.A, MeiraGTx, RegenxBio, Asklepios Biopharmaceutical, Audentes Therapeutics, and others.

Emerging Adeno-associated Virus Vectors in Gene Therapy Drugs Under Different Phases of Clinical Development Include:
• AAV2/8LSPhGAA: Asklepios Biopharmaceutical
• AAV CNGA3: MeiraGTx
• GT 005: Gyroscope Therapeutics
• MCO-010: Nanoscope TherapeuticsXX
• NFS-01: Neurophth biological tech
• LYS-SAF302: Lysogene
• SPK-9001: Spark Therapeutics
• SPK-8011: Spark Therapeutics

Get a Free Sample PDF Report to know more about Adeno-associated Virus Vectors in Gene Therapy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Adeno-associated Virus Vectors in Gene Therapy Pipeline Analysis:
The Adeno-associated Virus Vectors in Gene Therapy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Adeno-associated Virus Vectors in Gene Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adeno-associated Virus Vectors in Gene Therapy Treatment.
• Adeno-associated Virus Vectors in Gene Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adeno-associated Virus Vectors in Gene Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adeno-associated Virus Vectors in Gene Therapy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Adeno-associated Virus Vectors in Gene Therapy product details are provided in the report. Download the Adeno-associated Virus Vectors in Gene Therapy pipeline report to learn more about the emerging Adeno-associated Virus Vectors in Gene Therapy therapies at: https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Adeno-associated Virus Vectors in Gene Therapy Pipeline Market Drivers
• Increasing incidence of hematological and genetic disorders
• Favorable Research and Development Activities
• Increase in government support, ethical acceptance of gene therapy

Adeno-associated Virus Vectors in Gene Therapy Pipeline Market Barriers
• Multiple technological challenges
• Unwanted immune responses

Scope of Adeno-associated Virus Vectors in Gene Therapy Pipeline Drug Insight
• Coverage: Global
• Key Adeno-associated Virus Vectors in Gene Therapy Companies: Asklepios Biopharmaceutical, MeiraGTx, Gyroscope Therapeutics, Nanoscope Therapeutics, Neurophth biological tech, Lysogene, Spark Therapeutics, and others
• Key Adeno-associated Virus Vectors in Gene Therapy Therapies: AAV2/8LSPhGAA, AAV CNGA3, GT 005, MCO-010, NFS-01, LYS-SAF302, SPK-9001, SPK-8011, and others
• Adeno-associated Virus Vectors in Gene Therapy Therapeutic Assessment: Adeno-associated Virus Vectors in Gene Therapy current marketed and Adeno-associated Virus Vectors in Gene Therapy emerging therapies
• Adeno-associated Virus Vectors in Gene Therapy Market Dynamics: Adeno-associated Virus Vectors in Gene Therapy market drivers and Adeno-associated Virus Vectors in Gene Therapy market barriers

Request for Sample PDF Report for Adeno-associated Virus Vectors in Gene Therapy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Adeno-associated Virus Vectors in Gene Therapy Report Introduction
2 Adeno-associated Virus Vectors in Gene Therapy Executive Summary
3 Adeno-associated Virus Vectors in Gene Therapy Overview
4 Adeno-associated Virus Vectors in Gene Therapy- Analytical Perspective In-depth Commercial Assessment
5 Adeno-associated Virus Vectors in Gene Therapy Pipeline Therapeutics
6 Adeno-associated Virus Vectors in Gene Therapy Late Stage Products (Phase II/III)
7 Adeno-associated Virus Vectors in Gene Therapy Mid Stage Products (Phase II)
8 Adeno-associated Virus Vectors in Gene Therapy Early Stage Products (Phase I)
9 Adeno-associated Virus Vectors in Gene Therapy Preclinical Stage Products
10 Adeno-associated Virus Vectors in Gene Therapy Therapeutics Assessment
11 Adeno-associated Virus Vectors in Gene Therapy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Adeno-associated Virus Vectors in Gene Therapy Key Companies
14 Adeno-associated Virus Vectors in Gene Therapy Key Products
15 Adeno-associated Virus Vectors in Gene Therapy Unmet Needs
16 Adeno-associated Virus Vectors in Gene Therapy Market Drivers and Barriers
17 Adeno-associated Virus Vectors in Gene Therapy Future Perspectives and Conclusion
18 Adeno-associated Virus Vectors in Gene Therapy Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Adeno-associated Virus Vectors in Gene Therapy drugs and therapies-
https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Adeno-associated Virus Vectors in Gene Therapy Market https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Adeno-associated Virus Vectors in Gene Therapy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Adeno-associated Virus Vectors in Gene Therapy Epidemiology https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Adeno-associated Virus Vectors in Gene Therapy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.